Although sphingomyelin (SM) is the most abundant phospholipid in the plasma, next to phosphatidylcholine (PC), its physiological function in plasma is unclear. Here we employed plasma from various genetic models of mice which naturally differ in their plasma SM/PC ratios, to study the role of SM as a modulator of LCAT, the enzyme responsible for HDL maturation and the synthesis of cholesteryl esters (CE) in normal plasma. Serine palmitoyltransferase deficient mice, and SM synthase deficient mice, both of which have below normal SM/PC ratios, showed significantly elevated LCAT activities when assayed with the endogenous substrates. On the other hand, LDL receptor knockout mice, and apo E knockout mice, both of which have high SM/PC ratios, had markedly reduced (-80%) LCAT activities. The LCAT levels in plasma, as assayed with an exogenous substrate, were similar in all groups, except for a 45% decrease in apo E knockout mice. Plasma samples with high SM/PC ratios had lower percentage of 20:4, 22:5, and 22:6 CE all of which are formed by LCAT, and a higher percentage of the atherogenic 18:1 CE which is mainly derived from the action of liver ACAT, showing that in vivo, the contribution of LCAT to plasma CE is reduced while that of liver ACAT is increased. These results show that SM is a physiological modulator of LCAT activity as well as plasma CE composition, and this may contribute to the previously reported pro-atherogenic effect of high plasma SM levels.
Introduction:
Lecithin-cholesterol acyltransferase (LCAT) plays a critical role in the reverse cholesterol transport pathway by esterifying free cholesterol (FC) derived from the peripheral tissues and driving the cholesterol efflux forward [1, 2] . The majority of the cholesteryl ester (CE) present in human plasma is derived from the action of LCAT [3] , and the enzyme activity is positively correlated with HDL levels [4, 5] . The regulation of LCAT activity is therefore important not only in lipoprotein metabolism but also in atherogenesis. Low LCAT activity has been shown to be a strong positive marker for ischemic heart disease [6] . The complete absence of LCAT in plasma results in a drastic reduction in HDL, and in several disorders including renal disease, anemia, corneal opacity, and cardiovascular disease (CVD) [2, 7] . However, high LCAT levels in plasma, as determined by the exogenous substrate assay or LCAT mass, are not necessarily protective against CVD [8] , indicating that the esterification rate of the endogenous substrate is physiologically more relevant. Since the expression of LCAT in liver as well as its levels in plasma do not vary significantly in the general population [9] , the regulation of cholesterol esterification occurs mainly from the modulation of the enzyme activity by its substrates, activators, and inhibitors in the plasma. We previously showed that sphingomyelin (SM), the second most abundant phospholipid in the lipoproteins, is an inhibitor of LCAT [10] and of the secretory phospholipases [11] [12] [13] , and that the in vitro the activities of these enzymes are negatively correlated with the SM/phosphatidylcholine (PC) ratio in the lipoprotein substrates. Although the in vitro inhibitory effect of SM on LCAT activity has now been reported by several laboratories [14] [15] [16] , the physiological relevance of this inhibition has not been established. In addition to the LCAT-derived CE which is predominantly polyunsaturated, varying amounts of CE derived from the action of acyl CoA: cholesterol acyltransferase (ACAT), which is predominantly 18:1, are present in the plasma. Since the atherogenic potential of ACAT-derived CE is much higher than that of LCAT-derived CE [17] , the relative contribution of these two enzymes significantly affects the atherogenic risk.
In this study, we determined the LCAT activity and the CE composition in mouse plasma samples which have inherent differences in their SM levels due to genetic abnormalities. The SM levels are elevated naturally in apo E deficient mice because of an increased synthesis in liver and decreased degradation [18] . Similarly the plasma SM levels are elevated in LDL receptor deficient mice primarily because of the accumulation of apo B lipoproteins which are rich in SM [10] . On the other hand, there are two mouse models available where the plasma SM levels are significantly reduced because of mutations in the SM synthetic enzymes. One is the heterozygous deficiency of long chain base 2 of serine palmitoyltransferase (SPT), the rate limiting enzyme in the SM biosynthetic pathway [19] . The homozygous deficiency of SPT is embryonic lethal. The second model of lower SM level is the knockout of sphingomyelin synthase 2 (SMS2), the terminal enzyme in the SM biosynthetic pathway [20] . These mouse models with decreased plasma SM levels have been shown to have reduced risk of inflammation, insulin resistance, and atherosclerosis [19] [20] [21] . The availability of the mouse models that naturally contain varying levels of SM/PC ratios in plasma provides an opportunity to test the hypothesis that plasma SM levels directly regulate LCAT reaction in vivo, and consequently modulate the composition of plasma CE species. The results presented here show that the SM-deficient animals (with lower SM/PC ratios) indeed show a significant increase in the LCAT activity when assayed with endogenous substrates, whereas the animals with higher than normal SM/PC ratios exhibit an inhibition of the enzyme activity. The CE fatty acid composition also reflected the changes in LCAT activity, with the plasma samples with decreased LCAT activity showing lower percentage of 20:4 and 22:6, the LCAT-derived CE species, and higher percentage of 16:0 and 18:1, the ACAT-derived CE species. These results therefore support the hypothesis that plasma SM is a physiological regulator of cholesterol esterification in the lipoproteins.
Materials and Methods

Plasma samples:
All animal studies were approved by the Animal Care Committees = 10) . Not all assays were performed in some samples because of insufficient volume of plasma. Free and total cholesterol in the plasma were determined with Amplex Red reagent kit (Invitrogen), the former by the elimination of cholesteryl ester hydrolase from the assay mixture. Cholesteryl ester (CE) content was calculated as the difference between total and free cholesterol values.
LCAT assay:
LCAT activity was assayed by both the endogenous substrate and the exogenous substrate methods as described previously [23] . Briefly, for the endogenous assay, the plasma sample (30 µl) was equilibrated with human serum albumin-3 H cholesterol emulsion [24] in presence of 1 mM DTNB, a specific inhibitor of LCAT. The inhibition was then released by the addition of ß mercaptoethanol (5 mM) and the enzyme reaction was allowed to proceed for 30 min at 37 0 C. The reaction was stopped by the addition of 1 ml ethanol containing 50 µg each of cholesterol and cholesteryl oleate. The lipids were extracted 2 times with 2 ml each hexane, and the pooled hexane extracts were concentrated and separated by TLC, using petroleum ether: ethyl acetate (85: 15 v/v) as the solvent. The radioactivity in FC and CE spots was measured by liquid scintillation counting. The enzyme activity was expressed as fractional esterification rate (% of labeled cholesterol esterified/ 30 min) and as molar esterification rate (nmol of cholesterol esterified/ h/ ml of plasma).
For the exogenous substrate assay, proteoliposomes containing 14 C-labeled cholesterol , egg PC, and apo AI at molar ratios of 15:300:1 were prepared as described by Chen and Albers [25] . Plasma sample (20 µl) was incubated with proteoliposome substrate (containing 2.5 nmol cholesterol) in presence of 10 mM mercaptoethanol and 2.5 mg/ml of human serum albumin for 60 min and the % of labeled cholesterol esterified was determined as described above for the endogenous substrate. The proteoliposome assay is a direct measure of the active enzyme concentration in the plasma, and is not affected by the plasma activators and inhibitors [25] .
SMase treatment of plasma:
In some experiments the plasma samples were first treated with SMase to deplete the SM levels before the LCAT activity was assayed by the endogenous substrate assay. The plasma was incubated in presence of 1 mM DTNB and 1 mM Mn ++ with 1.5 units of S. aureus SMase C for 60 min. The plasma was then equilibrated with labeled cholesterol by incubation with albumin-3 H cholesterol complex for overnight at 4 0 C, and finally incubated in presence of 5 mM mercaptoethanol. The fractional and molar esterification rates were calculated as above.
Determination of phospholipids and cholesteryl esters by mass spectroscopy
Total lipids were extracted from plasma (20 µl) using Bligh and Dyer procedure [26] , after adding the internal standards (50 ng each of 15:0-15:0 PC, 17:0 LPC, and 12:0 SM and 50 µg of 17:0 CE). The solvent was evaporated and the total lipids were reconstituted in 1 ml chloroform: methanol: water (72:23:3 by vol). The identification and quantitation of CE and phospholipid species was carried out using an ABSciex QTRAP 5500 system coupled to an Agilent 1260 series liquid chromatograph. Lipids were separated on a normal phase column (Supelco Ascentis Si HPLC 3µ particle size, 10 cm x 2.1 mm) with a flow rate 0.2 ml/min using a gradient of two solvent mixtures (solvent A-chloroform: methanol: 
Statistical analyses
The statistical significance between WT and other groups was determined by the Student's t test (unpaired, 2 tailed), with p<0.05 taken as the significance level. Correlation between the variables was calculated by Pearson correlation.
Results:
Plasma lipid composition
The genetic backgrounds of all tested groups of mice were comparable. The SM/PC ratios of plasma from various mouse models, as determined by LC/MS/MS, are shown in Fig. 1 . The plasma from both Sptcl2 +/-and Sms2 -/-mice showed a significant decrease (about 30%) in SM/PC ratios compared to the wild type control (WT) mice. This decrease is due mostly to a decrease in plasma concentration of SM with no change in PC, as reported earlier [27] , [19] . On the other hand, the ratios were significantly higher than WT mice in ApoE -/-mice (+74%) and Ldlr -/-mice (+28%), due to a disproportionate increase in SM compared to PC, as reported in other studies [18, 28] .
The free cholesterol (FC) and cholesteryl ester (CE) concentrations and the FC/CE ratios are shown in Fig. 2 . The FC levels were lower than WT mice in Sptcl2 +/-and Sms2 -/-mice, although only the former was statistically significant. The FC values in both ApoE -/-and LDLR KO mice were significantly higher than in WT mice. The CE concentrations of Sptcl2 +/-and Sms2 -/-plasmas were in the normal range, whereas they were significantly higher in ApoE -/-and Ldlr -/-mice, as expected from the increased total cholesterol values. The FC/CE ratios, which inversely correlate with endogenous esterification efficiency, showed a significant decrease in SPT and SMS2 deficient mice, and a striking increase in the Ldlr -/-and ApoE -/-mice, indicating a higher esterification efficiency in the SM-deficient groups and a lower esterification efficiency in the high SM groups. Previous studies by Furbee et al [29] reported that the FC/CE ratio is increased in the ApoE -/-plasma although they found no significant change in the Ldlr -/-plasma.
LCAT activity
The LCAT activity in each plasma sample was assayed with both the endogenous substrates [24] and an exogenous proteoliposome substrate [25] . The endogenous activity is affected by the composition of lipoproteins, and the activators and inhibitors naturally present in the plasma, whereas the exogenous substrate assay measures the amount of active enzyme in the plasma since the substrates or activators are not limiting with respect to the amount of enzyme available [25] .
As shown in Fig. 3 , the activities with endogenous substrate were significantly higher in Sptcl2 
Molar activities
The molar esterification rates of cholesterol were calculated from the fractional esterification rates (with endogenous substrate) and the FC concentration of the plasma. The molar rates were significantly lower in Sptlc2 +/-plasma, despite the higher fractional rates because of the low FC concentration in the plasma (Fig. 4) . However the molar rate in the Sms2 -/-plasma was significantly higher than normal.
Despite the low fractional rates in the ApoE -/-and Ldlr -/-mice their molar rates were not significantly different from the WT because of the high FC concentration in their plasma.
Correlations
The LCAT activity (with endogenous substrate) correlated negatively with SM/PC ratios (Fig. 5, top) , as well as with FC/CE ratios (Fig. 5, middle) . There was a clear segregation of SM-rich plasma samples at the lower end of LCAT activities. It should be pointed out that the graphs include only the samples where both the enzyme activity and lipid estimations were performed on the same sample, and therefore did not include samples where one of the values was missing. There was also a positive correlation between the FC/CE ratios and the SM/PC ratios (Fig. 5, bottom) , again supporting the notion that plasma samples containing high SM concentration exhibit lower cholesterol esterification rate in vivo.
CE molecular species composition
LCAT is known to preferentially synthesize polyunsaturated cholesteryl esters in mouse plasma, since it predominantly transfers the sn-2 acyl group from PC. On the other hand the CE species formed by the liver ACAT (and secreted into plasma) are predominantly 18:1 species. Therefore the composition of plasma CE species can be used as a measure of the contribution of the two enzymes for the plasma CE content. As shown in Fig. 6 , the concentrations of 16:0, 16:1 and 18:1 CE species were significantly higher in both Ldlr -/-and ApoE -/-mice. There was also a significant decrease in the polyunsaturated CE in these genotypes, especially the 20:4 and 22:6 CE, which are formed predominantly, if not exclusively by the LCAT reaction [29] , supporting a reduced contribution of LCAT to the plasma CE species in vivo.
Interestingly, both ApoE -/-and Ldlr -/-plasma samples showed a significant increase in another polyunsaturated CE, namely 18:3 CE. This is also probably a product of ACAT reaction, since it has been reported that both 18:1 and 18:3 are better substrates than either 20:4 or 20:5 for liver ACAT2 [31] . There were no significant changes in the CE composition in Sms2 -/-mice compared to the control. In Sptcl2 +/-mice, however, there was a significant decrease in 16:0 CE, and a significant increase in 20:5 CE. There was also an increase in the percentage of 18:2, 20:4, and 22:6 CE species, although the increases were not statistically significant. All these results are consistent with an increased contribution of LCAT and decreased contribution of ACAT, in SM-poor plasma samples.
Discussion
Although SM is the second most abundant phospholipid in the plasma lipoproteins, its physiological function in plasma has not attracted much attention. Its concentration varies significantly between various lipoproteins and even the subfractions of lipoproteins [32] , suggesting that it is not merely fulfilling a structural role. Unlike PC, however, it is not a substrate for the lipolytic enzymes of plasma, and does not exchange easily between various lipoproteins. Based on its structural similarities with PC, and its resistance to lipolytic enzymes, we suggested that it serves as a competitive inhibitor of these enzymes, thus preventing the unregulated degradation of PC [10, 33] . In the past few years several of the lipolytic enzymes that utilize PC as substrate, including LCAT [10, [14] [15] [16] , secretory phospholipases group II, V, and X [11] [12] [13] 28] , as well as lipoprotein lipase [34] have been shown to be inhibited by SM in the in vitro assays. Recent results from our laboratory also showed that endothelial lipase, which is predominantly a phospholipase [35] , is inhibited by SM (manuscript in preparation). It is, however, necessary to show that the inhibition by SM is physiologically relevant and that it occurs in vivo. In the present study, we took advantage of the availability of mouse models that inherently differ in their plasma SM/PC ratios to address the physiological relevance of SM inhibition of LCAT reaction. The results presented clearly show that the SM/PC ratio of the plasma is inversely correlated with the cholesterol esterification rates supporting the hypothesis that SM is a physiological modulator of LCAT reaction. The differences in the plasma CE composition among the mouse models also support the presence of in vivo differences in the LCAT activities.
Although we found a strong negative correlation between plasma SM/PC ratio and the LCAT activity, these results do not necessarily prove a direct role of SM in the inhibition of LCAT. In an attempt to test whether the LCAT activity is activated by the depletion of SM in the SM-rich plasma, we treated the plasma from ApoE -/-and Ldlr -/-mice with bacterial sphingomyelinase (SMase) C before assaying for the LCAT activity. Our previous studies showed that such treatment of the lipoprotein substrates or the proteoliposome substrates by SMase activates the LCAT [10, 36] , as well as the secretory phospholipase reactions [11] [12] [13] . However, when the whole plasma was treated with SMase C, the cholesterol esterification was actually inhibited (results not shown), apparently because of the inactivation of LCAT during the SMase reaction. Temporary inhibition of LCAT with DTNB during SMase treatment, followed by the release of inhibition by mercaptoethanol also did not result in reactivation of the enzyme, suggesting an irreversible effect of SMase treatment on LCAT.
The reduction of LCAT activity in the ApoE -/-mice has previously been reported by Zhao et al [37] , but these authors attributed this to the deficiency of apo E itself, since apo E is one of the known apoprotein activators of the LCAT reaction [38] . However it is likely that the high SM levels in the plasma play a larger role than the absence of apo E, because of the following reasons. 1) the concentration of apo AI, the primary apoprotein activator of LCAT is not limiting in the ApoE -/-mice, and therefore it can compensate for the lack of apo E. 2) LCAT activity with the HDL substrate that contains only apo AI is 50-100 times higher than with the HDL substrate that contains only apo E [39] , showing that the loss of apo E may not be significant for the esterification of cholesterol in HDL. It is, however, possible that apo E deficiency specifically affects the LCAT activity on the apo B lipoproteins.
To our knowledge, the LCAT activity in Ldlr -/-mice has not been investigated using the endogenous substrate method. Two previous studies using the exogenous substrate method have reported no change in the LCAT activity [30] which is in agreement with the present studies (Fig. 3 ). This assay, however, would not reflect the effect of SM present in the endogenous lipoproteins. The CE fatty acid composition in these mice, however, shows a decreased contribution of LCAT for plasma cholesteryl esters in vivo [29] . It is therefore likely that the esterification of lipoprotein cholesterol is inhibited in vivo in LDL receptor deficiency.
In addition to affecting plasma HDL levels, the LCAT reaction significantly influences the plasma CE composition, which has been shown to be an independent risk factor for atherosclerosis in humans [40, 41] and in animal models [42] [43] [44] . LCAT generates predominantly polyunsaturated CE species, whereas the tissue ACAT reaction generates predominantly 18:1 CE. Therefore a reduction in the contribution of LCAT to plasma CE results in a relatively more saturated CE profile, which is positively correlated with the risk of atherosclerosis and CVD [40] [41] [42] [43] [44] . Several studies have shown that plasma SM is an independent risk factor for CVD [45] [46] [47] . It is possible that part of this pro-atherosclerotic effect of SM is due to its inhibition of LCAT activity which not only results in lower HDL levels, but also in the production of more saturated CE profile due to an increased contribution of liver ACAT to plasma CE. The molar activities were calculated by multiplying the fractional esterification rates (Fig. 3) with the concentration of FC in the plasma. 
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